We are pleased to announce that the United States District Court for the District of New Jersey has granted preliminary approval of the proposed class action settlement in Butler v. Breckenridge Pharmaceutical Inc. This case involves a recall of millions of duloxetine pills (generic Cymbalta) containing carcinogens known as nitrosamines.
This preliminary approval is an important milestone in the case and brings us one step closer to delivering meaningful relief to impacted consumers. The settlement, reached after thorough investigation, litigation, and negotiation, reflects our firm’s unwavering commitment to holding companies accountable and protecting the rights of consumers nationwide.
At The Block Firm, we take pride in our work on behalf of individuals harmed by corporate misconduct. Our class action and pharmaceutical litigation team is dedicated to ensuring fairness, promoting transparency, and achieving justice—especially where public health and consumer trust are at stake.
To learn more about our class action practice or current investigations, please visit our blog here, and if you would like to contact us, please do so here.
